These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 25560446)

  • 1. Duration of pertussis immunity after DTaP immunization: a meta-analysis.
    McGirr A; Fisman DN
    Pediatrics; 2015 Feb; 135(2):331-43. PubMed ID: 25560446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waning protection after fifth dose of acellular pertussis vaccine in children.
    Klein NP; Bartlett J; Rowhani-Rahbar A; Fireman B; Baxter R
    N Engl J Med; 2012 Sep; 367(11):1012-9. PubMed ID: 22970945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
    Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.
    Esposito S; Agliardi T; Giammanco A; Faldella G; Cascio A; Bosis S; Friscia O; Clerici M; Principi N
    Infect Immun; 2001 Jul; 69(7):4516-20. PubMed ID: 11401994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of Immunity and Effectiveness of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children.
    Domenech de Cellès M; Rohani P; King AA
    JAMA Pediatr; 2019 Jun; 173(6):588-594. PubMed ID: 31009031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waning immunity to pertussis following 5 doses of DTaP.
    Tartof SY; Lewis M; Kenyon C; White K; Osborn A; Liko J; Zell E; Martin S; Messonnier NE; Clark TA; Skoff TH
    Pediatrics; 2013 Apr; 131(4):e1047-52. PubMed ID: 23478868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines.
    Rennels MB; Deloria MA; Pichichero ME; Losonsky GA; Englund JA; Meade BD; Anderson EL; Steinhoff MC; Edwards KM
    Pediatrics; 2000 Jan; 105(1):e12. PubMed ID: 10617749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
    Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination.
    van der Lee S; Sanders EAM; Berbers GAM; Buisman AM
    Vaccine; 2018 Jan; 36(2):220-226. PubMed ID: 29199041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine.
    Ausiello CM; Lande R; Urbani F; Di Carlo B; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A
    J Infect Dis; 2000 Jun; 181(6):1989-95. PubMed ID: 10837180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
    Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
    Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
    Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH
    J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine.
    Klein NP; Bartlett J; Fireman B; Aukes L; Buck PO; Krishnarajah G; Baxter R
    Vaccine; 2017 Jun; 35(26):3395-3400. PubMed ID: 28506516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
    Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
    Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.